Gerlach T, Elbahesh H, Saletti G, Rimmelzwaan G. Recombinant influenza A viruses as vaccine vectors. Expert Rev Vaccines. 2019 Feb 19.. Abstract
submitted by kickingbird at Feb, 21, 2019 from Expert Rev Vaccines. 2019 Feb 19. (via https://www.ncbi.nlm.nih.gov/pubmed/30777467)
Various viruses, including poxviruses, adenoviruses and vesicular stomatitis virus, have been considered as vaccine vectors for the delivery of antigens of interest in the development of vaccines against ...
Hu Y, et al. Immunogenicity and safety of a trivalent inactivated influenza vaccine produced in Shenzhen, China versus a comparator influenza vaccine: a phase IV randomized study. Hum Vaccin Immunother. 2019 Feb 19. Abstract
submitted by kickingbird at Feb, 21, 2019 from Hum Vaccin Immunother. 2019 Feb 19 (via https://www.ncbi.nlm.nih.gov/pubmed/30779689)
Seasonal influenza causes substantial morbidity and mortality in China, which largely results from limited vaccine accessibility and poor vaccination coverage. Since 2013, Sanofi Pasteur's facilities in ...
Byrne-Nash RT, et al. A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines. NPJ Vaccines. 2019 Jan 22;4:3. Abstract
submitted by kickingbird at Jan, 26, 2019 from NPJ Vaccines. 2019 Jan 22;4:3 (via https://www.ncbi.nlm.nih.gov/pubmed/30675394)
Neuraminidase (NA) immunity leads to decreased viral shedding and reduced severity of influenza disease; however, NA content in influenza vaccines is currently not regulated, resulting in inconsistent ...
Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD? and VANTAFLU? in South Korean Subjects Aged ≥65 Years. Infect Chemother. 2018 Dec;50(4):301-310. Abstract
submitted by kickingbird at Jan, 7, 2019 from Infect Chemother. 2018 Dec;50(4):301-310 (via https://www.ncbi.nlm.nih.gov/pubmed/30600653)
BACKGROUD: Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study ...
Job ER, et al. Broadened immunity against influenza by vaccination with computationally designed influenza virus N1 neuraminidase constructs. NPJ Vaccines. 2018 Nov 29;3:55. Abstract
submitted by kickingbird at Dec, 6, 2018 from NPJ Vaccines. 2018 Nov 29;3:55 (via https://www.ncbi.nlm.nih.gov/pubmed/30510776)
Split inactivated influenza vaccines remain one of the primary preventative strategies against severe influenza disease in the population. However, current vaccines are only effective against a limited ...
Souza CK, et al. Serological surveillance and factors associated with influenza A virus in backyard pigs in Southern Brazil. Zoonoses Public Health. 2018 Nov 28. Abstract
submitted by kickingbird at Dec, 4, 2018 from Zoonoses Public Health. 2018 Nov 28 (via https://www.ncbi.nlm.nih.gov/pubmed/30485723)
Backyard pig populations are not monitored for influenza A virus (IAV) in Brazil and there are limited data about seroprevalence and risk factors in these populations. Our goal was to assess possible factors ...
Bhardwaj J, Sharma A, Jang J. Vertical flow-based paper immunosensor for rapid electrochemical and colorimetric detection of influenza virus using a different pore size sample pad. Biosens Bioelectron. 2018 Oct 19;126:36-43. Abstract
submitted by kickingbird at Nov, 3, 2018 from Biosens Bioelectron. 2018 Oct 19;126:36-43 (via https://www.ncbi.nlm.nih.gov/pubmed/30388552)
We present a novel vertical flow-based paper immunosensor for the rapid and sensitive electrochemical and colorimetric detection of influenza H1N1 viruses using a different pore size (DP) sample pad. The ...
Hussain S, et al. Mutation of influenza A virus PA-X decreases pathogenicity in chicken embryos and can increase the yield of reassortant candidate vaccine viruses. J Virol. 2018 Oct 31.. Abstract
submitted by kickingbird at Nov, 3, 2018 from J Virol. 2018 Oct 31. (via https://www.ncbi.nlm.nih.gov/pubmed/30381488)
The PA-X protein of influenza A virus has roles in host cell shut-off and viral pathogenesis. While most strains are predicted to encode PA-X, strain-dependent variations in activity have been noted. We ...
van der Lubbe JEM, et al. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice. Front Immunol. 2018 Oct 12;9:2350. Abstract
submitted by kickingbird at Oct, 31, 2018 from Front Immunol. 2018 Oct 12;9:2350 (via https://www.frontiersin.org/articles/10.3389/fimmu.2018.0235)
Seasonal influenza vaccines are updated almost annually to match the antigenic drift in influenza hemagglutinin (HA) surface glycoprotein. A new HA stem-based antigen, the so-called "mini-HA," was recently ...
St Charles KM, et al. Avian Influenza in the U.S. Commercial Upland Game Bird Industry: An Analysis of Selected Practices as Potential Exposure Pathways and Surveillance System Data Reporting. Avian Dis. 2018 Sep;62(3):307-315.. Abstract
submitted by kickingbird at Oct, 21, 2018 from Avian Dis. 2018 Sep;62(3):307-315. (via https://www.ncbi.nlm.nih.gov/pubmed/30339513)
Producing a smaller yield of higher-value birds compared to conventional poultry production, the U.S. commercial upland game bird industry deals primarily in the sale of live birds for recreational hunting. ...
Claeys C, et al. Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Na?ve Children. Pediatr Infect Dis J. 2018 Oct 15.. Abstract
submitted by kickingbird at Oct, 18, 2018 from Pediatr Infect Dis J. 2018 Oct 15. (via https://www.ncbi.nlm.nih.gov/pubmed/30325891)
BACKGROUND: It has not yet been demonstrated whether two doses of inactivated quadrivalent influenza vaccine (IIV4) prime a booster response in infants. We evaluated the anamnestic immune response to an ...
Loebermann M, et al. A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Opt. Infection. 2018 Oct 8.. Abstract
submitted by kickingbird at Oct, 15, 2018 from Infection. 2018 Oct 8. (via https://www.ncbi.nlm.nih.gov/pubmed/30298473)
Vaccination is an essential tool in reducing the impact of seasonal influenza infections. The viral strains responsible for seasonal outbreaks vary annually, and preventive vaccines have to be adapted ...
Nelson SW, etc.,al. Evaluation of nonwoven fabrics for nasal wipe sampling for influenza A virus in swine. J Vet Diagn Invest. 2018 Sep 28:1040638718803999. Abstract
submitted by kickingbird at Oct, 3, 2018 from J Vet Diagn Invest. 2018 Sep 28:1040638718803999 (via https://www.ncbi.nlm.nih.gov/pubmed/30264670)
Influenza A virus (IAV) is a zoonotic pathogen threatening animal and public health; therefore, detection and monitoring of IAV in animal populations are critical components of a surveillance program. ...
Klepser ME, Adams AJ. Pharmacy-based management of influenza: lessons learned from research. Int J Pharm Pract. 2018 Sep 28.. Abstract
submitted by kickingbird at Oct, 3, 2018 from Int J Pharm Pract. 2018 Sep 28. (via https://www.ncbi.nlm.nih.gov/pubmed/30265414)
Recently, several jurisdictions have pursued legislative and regulatory changes to allow pharmacy-based influenza management models in which pharmacists can initiate appropriate antiviral therapy in community ...
Scott LJ. Peramivir: A Review in Uncomplicated Influenza. Drugs. 2018 Sep 8.. Abstract
submitted by kickingbird at Sep, 13, 2018 from Drugs. 2018 Sep 8. (via https://www.ncbi.nlm.nih.gov/pubmed/30196350)
Intravenous peramivir (Alpivab?; Rapivab?; Rapiacta?; PeramiFlu?), the most recent globally approved inhibitor of influenza neuraminidase, is indicated for the treatment of uncomplicated influenza in adults ...
Wang C, Zhou J, Zhang C, Liu Z, Liu Y, Cai K. Adjuvant Activity of Bursal Pentapeptide-(III-V) in Mice Immunized with the H9N2 Avian Influenza Vaccine. Protein Pept Lett. 2018 Aug 5. Abstract
submitted by kickingbird at Aug, 11, 2018 from Protein Pept Lett. 2018 Aug 5 (via https://www.ncbi.nlm.nih.gov/pubmed/30081784)
Bursal pentapeptide (BPP)-(III-V) are peptides isolated from the bursa of Fabricius (BF). The peptides' adjuvant activities were evaluated in mice immunized with the H9N2 avian influenza vaccine. The results ...
MEDINA J, Guillot V, Totain E, Rouleau M, et al. Vero/CHOK1, a novel mixture of cell lines that is optimal for the rescue of influenza A vaccine seeds. J Virol Methods. 2013 Oct 23. Abstract
submitted by kickingbird at Nov, 4, 2013 from J Virol Methods. 2013 Oct 23 (via http://www.ncbi.nlm.nih.gov/pubmed/24161812)
Seasonal and pandemic influenza vaccine manufacturing is challenged with a tight production schedule. Reverse genetics constitutes a rapid method for creating viruses. Vero and CHOK1 cells were found to ...
Lenzer J. Belief not science is behind flu jab promotion, new report says. BMJ 2012;345:e7856. Abstract
submitted by kickingbird at Feb, 3, 2013 from BMJ 2012;345:e7856 (via http://www.bmj.com/content/345/bmj.e7856?view=long&pmid=2316)
An independent meta-analysis of vaccines against influenza has found that claims of benefit have been significantly exaggerated.
The report, released last month by the University of Minnesota’s Center ...
WER. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. WHO. Abstract
submitted by kickingbird at Oct, 22, 2011 from WHO (via http://www.who.int/wer/2011/wer8643/en/index.html)
Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness Standardization of terminology of the pandemic A(H1N1) 2009 ...
BARRETT PN, Berezuk G, Fritsch S, Aichinger G, et. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2011 Feb 26;377(9767):751-9. Epub 2011 Feb. Abstract
submitted by kickingbird at Mar, 4, 2011 from Lancet. 2011 Feb 26;377(9767):751-9. Epub 2011 Feb (via http://www.ncbi.nlm.nih.gov/pubmed/21329971)
BACKGROUND: The use of cell-culture technologies for the manufacture of influenza vaccines might contribute to improved strain selection and robust vaccine supplies. We investigated the safety, immunogenicity, ...
50 items, 20/Page, Page[2/3][|<<] [|<]    [>|] [>>|]
Browse by Category
Learn about the flu news, articles, events and more
Subscribe to the weekly F.I.C newsletter!